Aeovian Pharmaceuticals | Valuation, Funding Rounds & Stock Price | Caplight

Aeovian Pharmaceuticals

Private

Berkeley, California
Healthcare & Life Sciences
https://www.aeovian.com/

Last Round
Series B
Dec 16, 2025

Total Funding Raised
$142M

Momentum
Top 25% of companies Caplight tracks

Company Overview

Aeovian Pharmaceuticals is a biotechnology company that develops targeted and highly selective small molecule therapeutics to restore cellular metabolic quality control for the treatment of rare and age-related diseases.

Sector
Healthcare & Life Sciences

Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model
B2B

Customer Profile
Services & Consulting

AI Layer
Non-AI

Keywords
biotechnology, mTORC1 inhibitor, drug discovery, rare disease, Tuberous Sclerosis Complex, TSC, precision medicine, clinical-stage biotech, refractory epilepsy, CD38 inhibitor, small-molecule therapeutics, drug development, clinical trials, biotech startup, therapeutic pipeline

Historical Pricing

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Aeovian Pharmaceuticals Comparables

Compare Aeovian Pharmaceuticals with similar companies based on industry and business-model similarity.

Company Similarity Market Cap
Cambrian Bio 82% Unlock
Aukera Therapeutics 77% Unlock
Novartis 74% Unlock
Comparable company 50% Unlock

Aeovian Pharmaceuticals Funding Rounds

Historical fundraising activity

Round Date Amount Raised Valuation Investors Sources
Series B Dec 16, 2025 Unlock Unlock Unlock Unlock
Series A Extension Mar 28, 2024 Unlock Unlock Unlock Unlock
Series A Oct 3, 2019 Unlock Unlock Unlock Unlock
Seed Dec 11, 2017 Unlock Unlock Unlock Unlock

Key People

Founding team and executive leadership

Allison Hulme
CEO
LinkedIn profile

Micah Zajic
Chief Financial Officer
LinkedIn profile

Aeovian Pharmaceuticals Investors

Investor Rounds
Apollo Ventures Seed
SymBiosis Capital Management Series B
CTI Life Sciences Fund Series B
TSC Alliance Endowment Fund Series B
Hevolution Foundation Series B, Series A Extension
LUMA Partners Series B
Foresite Capital Series B

Market signals

Monthly visitors increased 133% MoM, reaching 1.6K.

$55M Series B round completed.

Aeovian Pharmaceuticals Filings

Typed Date Amount Offered Amount Sold Filing Pages Download
Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation
Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation
Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation
Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation

Frequently Asked Questions

Common questions about Aeovian Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

Headquarters: Berkeley, California
Employee Range: 13
Year Founded: 2017
Last Funding: Dec 16, 2025